MedTrace Logo

Suprachoroidal Administration in Subjects With Metastases to the Choroid

NCT06643884 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-13

No results posted yet for this study

Summary

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.

Conditions

  • Eye Cancer
  • Primary Cancer

Interventions

DRUG

AU-011

AU-011 Via Suprachoroidal Administration with laser treatment

DEVICE

SCS Microinjector

Suprachoroidal Injection Device

DEVICE

Laser

Laser Administration

Sponsors & Collaborators

  • Aura Biosciences

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Aura Biosciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-16
Primary Completion
2026-11-30
Completion
2027-10-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06643884 on ClinicalTrials.gov